A prominently published study reported an improvement in mortality in acute respiratory distress syndrome (ARDS) patients who received early treatment with the paralyzing agent cisatracurium. [1] ...
CHICAGO--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. (“Meitheal”), announced today that it is voluntarily recalling one (1) lot of Cisatracurium Besylate Injection, USP 10mg per 5mL to the user ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results